| Species Reactivity | Human |
| Clone | demcizumab |
| Source/Isotype | Human IgG2 (S377A,delta447K), Kappa |
| Application | / |
| Specificity | Detects DLL4 |
| Gene | DLL4 |
| Other Names | Delta4 |
| Gene ID | 54567 (Human) |
| Background | Demcizumab (dancizumab, OMP-21M18) is a humanized monoclonal antibody (IGG2) developed by OncoMed Pharmaceuticals, targeting DLL4(Delta-like ligand 4) , which belongs to the Notch signaling pathway inhibitor. The core mechanism is the inhibition of the Notch pathway by blocking the binding of DLL4 to NOTCH1/4 receptors, and the inhibition of the Notch signaling pathway by the DLL4-like ligand, induction of tumorigenic “Non-functional angiogenesis”(vascular endothelial hyperproliferation but lack of intact lumen and blood flow perfusion, aggravating tumor hypoxia) and reduction of tumor stem cell (CSCs) frequency, while potentially modulating the immune microenvironment. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human |
| Clone | demcizumab |
| Source/Isotype | Human IgG2 (S377A,delta447K), Kappa |
| Application | / |
| Specificity | Detects DLL4 |
| Gene | DLL4 |
| Other Names | Delta4 |
| Gene ID | 54567 (Human) |
| Background | Demcizumab (dancizumab, OMP-21M18) is a humanized monoclonal antibody (IGG2) developed by OncoMed Pharmaceuticals, targeting DLL4(Delta-like ligand 4) , which belongs to the Notch signaling pathway inhibitor. The core mechanism is the inhibition of the Notch pathway by blocking the binding of DLL4 to NOTCH1/4 receptors, and the inhibition of the Notch signaling pathway by the DLL4-like ligand, induction of tumorigenic “Non-functional angiogenesis”(vascular endothelial hyperproliferation but lack of intact lumen and blood flow perfusion, aggravating tumor hypoxia) and reduction of tumor stem cell (CSCs) frequency, while potentially modulating the immune microenvironment. |
| Storage | Store at 2-8℃ short term (1-2 weeks).Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
